What to Do When Itraconazole Fails for Lymphocutaneous Sporotrichosis

Lymphocutaneous sporotrichosis typically responds to a standard oral course of itraconazole. When skin lesions do not show the expected clinical improvement — or fail to fully resolve — a defined next-line protocol applies.

Previous treatment — inadequate response

Prior therapy: Itraconazole (oral)

Goals not achieved: Clinical improvement of skin lesions, ordinarily expected within 4 weeks of starting therapy, and eventual complete resolution of all lesions.

Next-line approach (partial overview)

When itraconazole does not achieve adequate lesion response, the protocol calls for a modified antifungal strategy — either through intensification of the current approach or substitution with an alternative oral antifungal agent.

Full agent selection, dosing, and regimen sequence available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/522765

Patients who do not respond to treatment should be given a higher dosage of itraconazole (200 mg twice daily; A-II), terbinafine at a dosage of 500 mg orally twice daily (A-II), or SSKI initiated at a dosage of 5 drops (using a standard eye-dropper) 3 times daily, increasing as tolerated to 40–50 drops 3 times daily (A-II).

View source ↗